300 related articles for article (PubMed ID: 29284110)
41. The potent small molecule integrin antagonist THR-687 is a promising next-generation therapy for retinal vascular disorders.
Hu TT; Vanhove M; Porcu M; Van Hove I; Van Bergen T; Jonckx B; Barbeaux P; Vermassen E; Feyen JHM
Exp Eye Res; 2019 Mar; 180():43-52. PubMed ID: 30472075
[TBL] [Abstract][Full Text] [Related]
42. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration.
Hollanders K; Van Bergen T; Kindt N; Castermans K; Leysen D; Vandewalle E; Moons L; Stalmans I
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1335-48. PubMed ID: 25626969
[TBL] [Abstract][Full Text] [Related]
43. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
[TBL] [Abstract][Full Text] [Related]
44. miRNA involvement in angiogenesis in age-related macular degeneration.
Wang L; Lee AY; Wigg JP; Peshavariya H; Liu P; Zhang H
J Physiol Biochem; 2016 Dec; 72(4):583-592. PubMed ID: 27349759
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic Efficacy of a Novel Acetylated Tetrapeptide in Animal Models of Age-Related Macular Degeneration.
Koo HC; Baek YY; Choi JS; Kim YM; Sung B; Kim MJ; Kim JG; You JC
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33918777
[TBL] [Abstract][Full Text] [Related]
46. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
47. Genetic deficiency and pharmacological modulation of RORα regulate laser-induced choroidal neovascularization.
Liu CH; Yemanyi F; Bora K; Kushwah N; Blomfield AK; Kamenecka TM; SanGiovanni JP; Sun Y; Solt LA; Chen J
Aging (Albany NY); 2023 Jan; 15(1):37-52. PubMed ID: 36626253
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of Experimental Choroidal Neovascularization by a Novel Peptide Derived from Calreticulin Anti-Angiogenic Domain.
Bee YS; Ma YL; Chen J; Tsai PJ; Sheu SJ; Lin HC; Huang H; Liu GS; Tai MH
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30274378
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of RACK1 ameliorates choroidal neovascularization formation in vitro and in vivo.
Liu X; Zhu M; Yang X; Wang Y; Qin B; Cui C; Chen H; Sang A
Exp Mol Pathol; 2016 Jun; 100(3):451-9. PubMed ID: 27112838
[TBL] [Abstract][Full Text] [Related]
50. Targeted Intraceptor Nanoparticle for Neovascular Macular Degeneration: Preclinical Dose Optimization and Toxicology Assessment.
Zhang X; Bohner A; Bhuvanagiri S; Uehara H; Upadhyay AK; Emerson LL; Bondalapati S; Muddana SK; Fang D; Li M; Sandhu Z; Hussain A; Carroll LS; Tiem M; Archer B; Kompella U; Patil R; Ambati BK
Mol Ther; 2017 Jul; 25(7):1606-1615. PubMed ID: 28236576
[TBL] [Abstract][Full Text] [Related]
51. Mechanism of retinal pigment epithelium tear formation following intravitreal anti-vascular endothelial growth factor therapy revealed by spectral-domain optical coherence tomography.
Nagiel A; Freund KB; Spaide RF; Munch IC; Larsen M; Sarraf D
Am J Ophthalmol; 2013 Nov; 156(5):981-988.e2. PubMed ID: 23972309
[TBL] [Abstract][Full Text] [Related]
52. Relative contribution of VEGF and TNF-alpha in the cynomolgus laser-induced CNV model: comparing the efficacy of bevacizumab, adalimumab, and ESBA105.
Lichtlen P; Lam TT; Nork TM; Streit T; Urech DM
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4738-45. PubMed ID: 20393113
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of choroidal neovascularization by topical application of angiogenesis inhibitor vasostatin.
Sheu SJ; Bee YS; Ma YL; Liu GS; Lin HC; Yeh TL; Liou JC; Tai MH
Mol Vis; 2009 Sep; 15():1897-905. PubMed ID: 19768130
[TBL] [Abstract][Full Text] [Related]
54. Inhibition of experimental choroidal neovascularization in mice by anti-VEGFA/VEGFR2 or non-specific siRNA.
Gu L; Chen H; Tuo J; Gao X; Chen L
Exp Eye Res; 2010 Sep; 91(3):433-9. PubMed ID: 20599960
[TBL] [Abstract][Full Text] [Related]
55. Incomplete response to Anti-VEGF therapy in neovascular AMD: Exploring disease mechanisms and therapeutic opportunities.
Mettu PS; Allingham MJ; Cousins SW
Prog Retin Eye Res; 2021 May; 82():100906. PubMed ID: 33022379
[TBL] [Abstract][Full Text] [Related]
56. A novel vascular endothelial growth factor receptor 2 inhibitor, SU11248, suppresses choroidal neovascularization in vivo.
Takahashi H; Obata R; Tamaki Y
J Ocul Pharmacol Ther; 2006 Aug; 22(4):213-8. PubMed ID: 16910860
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of ocular neovascularization by novel anti-angiogenic compound.
Gau D; Vignaud L; Francoeur P; Koes D; Guillonneau X; Roy P
Exp Eye Res; 2021 Dec; 213():108861. PubMed ID: 34822853
[TBL] [Abstract][Full Text] [Related]
58. Andrographolide attenuates choroidal neovascularization by inhibiting the HIF-1α/VEGF signaling pathway.
Cui K; Liu J; Huang L; Qin B; Yang X; Li L; Liu Y; Gu J; Wu W; Yu Y; Sang A
Biochem Biophys Res Commun; 2020 Sep; 530(1):60-66. PubMed ID: 32828316
[TBL] [Abstract][Full Text] [Related]
59. The short-term effects of aflibercept on the size of choroidal neovascularization lesion in treatment-resistant neovascular age-related macular degeneration as determined by spectral-domain optical coherence tomography.
Abri Aghdam K; Seidensticker F; Pielen A; Framme C; Junker B
Lasers Surg Med; 2016 Sep; 48(7):668-77. PubMed ID: 27111455
[TBL] [Abstract][Full Text] [Related]
60. Emerging therapies for the treatment of neovascular age-related macular degeneration and diabetic macular edema.
Emerson MV; Lauer AK
BioDrugs; 2007; 21(4):245-57. PubMed ID: 17628122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
